Trial Profile
TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms TWiTCH
- 06 Dec 2016 Results of iron burden in the different organs (n=120) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results analysing agreement between measurements of dLIC over a period of one year by MRI R2 (FerriScan) and R2* methods, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Primary endpoint has been met. (TCD Mean Velocity at 24 months on the index side) as per rsults presented at the 58th Annual Meeting and Exposition of the American Society of Hematology